A double-blind, randomised, placebo controlled single ascending doses (SAD) and multiple ascending dose (MAD) study of MOR106 in healthy volunteers and patients with moderate to severe atopic dermatitis.

Trial Profile

A double-blind, randomised, placebo controlled single ascending doses (SAD) and multiple ascending dose (MAD) study of MOR106 in healthy volunteers and patients with moderate to severe atopic dermatitis.

Completed
Phase of Trial: Phase I

Latest Information Update: 17 Feb 2018

At a glance

  • Drugs MOR 106 (Primary)
  • Indications Atopic dermatitis; Chronic obstructive pulmonary disease; Osteoarthritis; Osteoporosis; Rheumatoid arthritis
  • Focus Adverse reactions; First in man
  • Sponsors Galapagos NV
  • Most Recent Events

    • 17 Feb 2018 Results presented in the Galapagos NV media release.
    • 17 Feb 2018 Results presented in a MorphoSys Media Release.
    • 17 Feb 2018 According to a MorphoSys media release, detailed results were presented at the American Academy of Dermatology (AAD) Annual Meeting 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top